AU672559B2 - A method of inducing superovulation in cattle - Google Patents
A method of inducing superovulation in cattle Download PDFInfo
- Publication number
- AU672559B2 AU672559B2 AU31706/95A AU3170695A AU672559B2 AU 672559 B2 AU672559 B2 AU 672559B2 AU 31706/95 A AU31706/95 A AU 31706/95A AU 3170695 A AU3170695 A AU 3170695A AU 672559 B2 AU672559 B2 AU 672559B2
- Authority
- AU
- Australia
- Prior art keywords
- inhibin
- cow
- superovulation
- follicle
- cattle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000283690 Bos taurus Species 0.000 title claims description 40
- 206010042573 Superovulation Diseases 0.000 title claims description 35
- 238000000034 method Methods 0.000 title claims description 25
- 230000001939 inductive effect Effects 0.000 title claims description 9
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 34
- 239000000893 inhibin Substances 0.000 claims description 33
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 22
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 22
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 210000002257 embryonic structure Anatomy 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000002255 vaccination Methods 0.000 claims description 11
- 210000002394 ovarian follicle Anatomy 0.000 claims description 9
- 230000016087 ovulation Effects 0.000 claims description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- 230000027758 ovulation cycle Effects 0.000 claims description 5
- 241000283073 Equus caballus Species 0.000 claims description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 claims description 2
- 230000029849 luteinization Effects 0.000 claims description 2
- 230000003529 luteolytic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000000431 corpus luteum hormone Substances 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000015278 beef Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 108010004250 Inhibins Proteins 0.000 description 25
- 102000002746 Inhibins Human genes 0.000 description 25
- 230000028327 secretion Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 206010062767 Hypophysitis Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 210000003635 pituitary gland Anatomy 0.000 description 5
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004409 cloprostenol Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000008217 follicular development Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000029860 luteolysis Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
-I-i 1 I
I
AUSTRALIA
Patents Act 1990 NATIONAL FEDERATION OF AGRICULTURAL COOPERATIVE
ASSOCIATIONS
ORIGINAL
B
a e e v .er 0 e ovn o S•o uvo u a o *M 6 COMPLETE SPECIFICATION STANDARD PATENT Invention Title: A method for inducing superovulation in cattle The following statement is a ftll description of this invention including the best method of performing it known to us:-
I
i' I- .1dq_
.WW
*1 7 BACKGROUND OF THE INVENTION The present invention relates to a method for inducing superovulation in cattle. More particularly, the present invention relates to a method for introducing superovulation at a higher and steady level to collect normal embryos efficiently. The present invention relates also to a method for reproducing cattle in which a significantly large number of ova or embryos can be collected when a cow having an increased number of ovarian follicles responsive to follicle-stimulating hormone to be injected during superovulation treatment is produced and subjected to the superovulation treatment.
0004 0000 on.
Description of the Related Prior Art Animals are classified into two categories, the monotocous animals cattle, horse and human being) which bring forth only one young per liter and the polytocous animals pig and dog) which bring forth a plurality of youngs per liter. It is considered 20 that the number of ovulations is controlled by hormones derived from hypothalamus-pituitary gland-gonads.
To collect many embryos as possible from cattle which is a monotocous animal, the superovulation technique for inducing ovulation of multiple ova has -2 been used. Usual method for superovulation in cattle comprises injection of an exogenous hormone iporcine follicle-stimulating hormone (FSH) or equine chorionic gonadotropin (eCG; formerly known as pregnant mare serum gonadotropin). That is, superovulation-inducing method in the embryo transfer technique has come into wide use as a technique for efficient bovine reproduction. The superovulation treatment in cattle can be induced by injecting follicle-stimulating hormone on day 9 to day 13 of estrous cycle to develop a large number of ovarian follicles, and by injecting prostaglandin F2a 48 to hours after the injection of follicle-stimulating hormone to induce luteolysis of the existing corpus lutea. The luteolysis results in ovulation by removing the inhibitory effect of progesterone on the action of hypothalamus and pituitary gland.
i o0'° On the other hand, it has been reported that immunological inhibition of inhibin which suppresses the secretion of follicle-stimulating hormone from pituitary 20 gland in cattle accelerates the secretion of folliclestimulating hormone from pituitary gland and consequently permits development of ovarian follicles and ovulation of multiple ova.
tilt Inhibin is a peptide hormone which is secreted in testis or ovarian follicles and suppresses the production and secretion of FSH in the pituitary gland.
In the 1980's, the rapid development of genetic engineering gradually revealed the whole aspect and i i 1
I
3 action of inhibin whose existence and structure had not been elucidated. It is being revealed that in mature cows, inhibin suppresses FSH secretion from the pituitary gland specifically. If inhibitory control of inhibin is possible in cows, secretion of endogenous FSH is accelerated. Therefore, it is expected that ovulation of multiple ova can be induced in every estrous cycle. In recent years, energetic attempts have been made in sheep and cattle to suppress inhibin by immunization and thereby increase the number of ova ovulated.
However, when standard superovulation method comprising injection of FSH or eCG is used, there is a i large variation in the number of ovarian follicles responsive to the hormone among treatments or cows.
This variation is one of the big problems in the art because it is difficult to collect embryos at a higher 4 and steady level with an excellent quality from superior-donor cows which have excellent genetical nature. Consequently, this variation increases the production cost per embryo.
Therefore, a considerable economical effect in the technique for bovine embryo transfer can be certainly obtained if cows which response at a higher and steady level to superovulation treatment are produced by elucidating the relationship between the responsiveness to superovulation and the state of p 4 ovarian follicles or hor.nones involved in follicular development, and carrying out a certain treatment.
It has been reported that there is a positive correlation between the number of ovarian follicles with of 4 to 6 mm in diameter at the initiation of superovulation treatment and the number of ova ovulated by the superovulation (Romero, Albert, Brink, Z.
and Seider, G.E. Jr., Theriogenology, 35, 265 (abstract) 1991). It has also been reported that the number of ova ovulated is decreased when the superovulation treatment is carried out in the luteal phase in which functional dominant follicles are present (Guilbaut, Grasso, Lussier, Rouillier, and Matton, J.
Reprod. Fertil., 91, 81-89, 1991; Huhtinen, Rainio Analto, Bredbacka, P. and Maki-Tanila, A., Theriogenology, 37, 457-463, 1992). In addition, it has been reported that inhibin secretion is increased with follicular development (Martin, Fogwell, R.L. and sq...
Ireland Biology of Reproduction, 44, 693-700, 20 1991). Recently, the present inventors found that the number of recruited follicles was increased by vaccinating a cow against inhibin. Although a manner in which dominant follicles affect on the response to superovulation treatment has not yet been elucidated, the above-mentioned reports suggest the following causal sequence: the presence of the dominant follicles the S" acceleration of inhibin secretion the decrease of the number of the recruited follicles the reduction of the response to superovulation treatment.
SUMMARY OF THE INVENTION From a new viewpoint, the present inventors found that the number of ova ovulated is significantly increased when a mature cow vaccinated against inhibin to have an increased number of ovarian follicles with a diameter of 4 to 6 mm is subjected to conventional superovulation treatment. When this technique is employed, the secretion of endogenous folliclestimulating hormone is accelerated. Therefore, no antibody against follicle-stimulating hormone is produced by repetition of the treatment, so that there is no fear of reduction of the effect.
15 BRIEF DESCRIPTION OF THE DRAWING Fig. 1 shows a change of antibody titer for inhibin caused by vaccination against inhibin.
4 DESCRIPTION OF THE PREFERRED EMBODIMENTS 44 .The present invention is illustrated below in detail with an example.
C
r t .i Example 1 The following experiments were carried out for S' counting ova ovulated by cows subjected to superovulation treatment after immunization against inhibin.
t O b .W 6 1. Experimental method Experiment 1 and experiment 2 were carried out.
Experiment 1 Five non-multiparous cows (Holstein) were used for confirming changes of the antibody titer for inhibin and the number of recruited follicles caused by vaccination against inhibin.
Experiment 2 Using 30 cows (Holstein and Japanese Black), the influence of vaccination against inhibin on the result of the superovulation treatment was investigated.
Five non-multiparous Holsteins and 9 multiparous Japanese Blacks were vaccinated against inhibin and then subjected to superovulation by the use of FSH by a usual method. As controls, 5 non-multiparous Holsteins and 11 multiparous Japanese Blacks were subjected to superovulation treatment without vaccination against inhibin.
The above groups were compared in the number of ova collected.
20 Antigen A product obtained by conjugating rabbit serum albumin to a polypeptice synthesized by copying the amino acid sequence from 1 to 26 (numbering from the Nterminal end) positions of the alpha-subunit of porcine 25 inhibin.
Test animals Non-multiparous Holsteins and multiparous Japanese Blacks, which had normal estrous cycles.
0 00 6 oo 000 oooe 00o0 DOO o 0 o 000000 a aoo 1 00 0 .o o 0o o 0 o00 0 0 000oo o aouo 0 kj9 0 0 D 00 0 o 00 0 0 00 0 006 0 0 o 0 0 0 Il
-U
-7- Immunization method Vaccination was employed. Primary injection was carried out as follows: a mixture of 1 mg of the peptide (corresponding to a fragment of inhibin) and complete Freund's adjuvant was injected to each test animal subcutaneously at 3 to 4 places. At 8 weeks and weeks after the primary injection, booster injections of the peptide was given at 0.5 mg as described above injection.
Follicle-stimulating hormone Extract from pituitary gland.
Luteolytic chemical Cloprostenol.
Superovulation treatment The superovulation treatment was started by FSH-injection at day 10 to day 12 of estrous cycle. The B; PSH was intramuscularly injected 6 times at 12-hour intervals in the following reducing dose: 6, 6, 5, 5, 3 .00.
and 3 mg. At 48 hours after the start of the FSH
S
r 20 injections, 750 pg of Cloprostenol was intramuscularly injected. Animals exhibiting estrus were artificially inseminated twice throughout estrus.
Determination of the number of ova ovulated, and embryos collected i 25 At day 7 to day 8 of rut after the superovulation treatment, embryos were collected nonsurgically from uterus. The number of the embryos
I
8 -8collected, the number of normal embryos and the percentage of the normal embryos were determined.
2. Results In the present study, vaccination against inhibin successfully induced elevated antibody titers against inhibin. When the antibody titers were elevated, the num er of recruited follicles (5 to 10 mm in diameter) showed a tendency to increase. When the number of recruited follicles was thus increased with an increase of the antibody titers for inhibin, the superovulation in the cows increased the number of ova and embryos collected without decrease of the percentage of normal embryos.
[Change of the number of recruited follicles during 15 vaccination against inhibin] t 4 4 4 4 4 0.
1 00 0 0 00 0 0 *00 00 0 a 0' 00.U C0 0 00 0 0 0 0 0 00 -00 00 00 000 0 Table 1 The number of follicles of 5-10 mm diameter Weeks after initiation 036 10 118 2279 Treated of036 10 118 2279 co vaccination Treatment Primary First Second injection booster booster 530 2 62 8 1 6 7 1 534 3 4 2 5 5 8 6 8 13 536 4 6 3 12 2 6 5 7 4 537 4 8 4 9 3 10 11 13 8 539 4 7 4 14 3 9 9 10 Mean S.D. 3.2±1.0 6.2±1.3 3. 0±0. 99.5±3.1 12.8±1.3 7.8±1.6 7.6±2.2 7.8±4.0 8.0±3.3 p From the results shown in Table 1, it can be seen that the number of recruited follicles with a diameter of 5 to 10 mm showed a tendency to increase after the primary injection and the boosters.
[Improvement of response to superovulation treatment by immunization against inhibin] Table 2 Results of superovulation induction and embryo collection Results of superovulation and ova collection Number Number Number P Percentage Group of of ova/ of normal of normal 'of norma! cows embryos embryo embryo collected (b/a 100) (b/alo) Control 14 5.9±4.1P 3.
7 ±3.5 P 62.7 Experiment 16 12.9±6.8P 8.9±4.0P 69.0 The superscript p indicates that there is a significant difference (p 0.01) in the same column (Student ttest).
mean S.D.
The superovulation treatment induced an increased number of both embryos collected and normal embryos in the inhibin-immunized group as compared to the untreated group (control).
ii r~r 4 e a *4, a4 (4 I. I i4 t 41 li L L t -I t '44' 444* S4 I 6 I
Claims (7)
1. A method for inducing superovulation in cattle, which comprises vaccinating a cow against inhibin present in its body to produce antibody therein, and then injecting a follicle-stimulating hormone exogenously.
2. A method according to Claim 1, wherein the follicle-stimulating hormone is follicle-stimulating hormone (FSH) or equine chorionic gonadotropin (eCG).
3. A method according to Claim 1, wherein the cow \O is a milk cow or beef cattle, which has normal estrous cycles after puberty.
4. A method according to Claim 1, wherein the vaccination against inhibin is carried out by using as antigen a product obtained by attaching albumin to a \S polypeptice synthesized by copying the amino acid sequence from 1 to 26 (numbering from the N-terminal end) positions of the alpha-subunit of porcine or bovine inhibin, and injecting a mixture of the antigen and an adjuvant to the cow several times subcutaneously.
5. A method according to Claim 1, wherein the vaccination against inhibin is carried out by injection 04a 0 S" of the antigen.
S6. A method for ovulation of a significantly large number of ova in cattle, which comprises S 25 subjecting a cow vaccinated against inhibin to usual superovulation treatment by injecting follicle- stimulating hormone to the cow on day 9 to day 13 of h 1, aanrr*rr~ rs~~ul--i---rrar raui--~a 12 luteal phase or after 7 to 12 days of residence of a corpus luteum hormone drug in the cow, injecting luteolytic preparation or removing the corpus luteum hormone preparation 2 or 3 days after the injection, and thereby inducing rut.
7. A method according to Claim 6, the antigen used for the vaccination is bovine or porcine natural (extracted) inhibin, a synthesized inhibin fragment, or copied inhibin. Dated this 14th day of September 1995 NATIONAL FEDERATION OF AGRICULTURAL COOPERATIVE ASSOCIATIONS Patent Attorney for the applicants F B RICE CO a o 7 o ao+ a O 0 o a o 9 a 0 o oo 0 at a e a 00 9 O 6 0 9 09 0 Ot 9 1 i i i, M- Ic ABSTRACT A method for inducing superovulation in cattle which comprises vaccinating a cow against inhibin, and then injectIng thereto follicle-stimulating hormone to cause ovulation of a large number of developed ovarian follicles. According to this method, normal embryos can be efficiently collected by inducing superovulation in cows at a higher and steady level. o 4.. 4 04 4o 4 *C 4 4 4C C+. tt e>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6-306274 | 1994-12-09 | ||
| JP6306274A JP2899534B2 (en) | 1994-12-09 | 1994-12-09 | Method of inducing superovulation in cattle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3170695A AU3170695A (en) | 1996-06-27 |
| AU672559B2 true AU672559B2 (en) | 1996-10-03 |
Family
ID=17955117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU31706/95A Ceased AU672559B2 (en) | 1994-12-09 | 1995-09-15 | A method of inducing superovulation in cattle |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2899534B2 (en) |
| AU (1) | AU672559B2 (en) |
| CA (1) | CA2158116A1 (en) |
| FR (1) | FR2727866B1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2768627B1 (en) * | 1997-09-19 | 2000-03-24 | Agronomique Inst Nat Rech | VETERINARY MEDICINAL PRODUCT CONTAINING MODIFIED EQUINE CHORIOGONADOTROPIN TO INDUCE OVULATION IN THE MARE AND STIMULATE THE PRODUCTION OF TESTOSTERONE IN THE STANDARD |
| KR101349009B1 (en) * | 2012-05-03 | 2014-01-21 | 대한민국 | In vivo production method of bovine embyos by emporary undernutrition |
| BR102014005376A2 (en) * | 2014-03-07 | 2016-02-10 | Ouro Fino Saúde Animal Ltda | inhibin alpha antigen, inhibin alpha coding gene, fusion protein encoding gene, process of obtaining inhibin alpha antigen, antigenic composition, use of inhibin alpha antigen, and use of antigenic composition |
| CN111134084A (en) * | 2020-01-06 | 2020-05-12 | 浙江省农业科学院 | Method for optimizing timing insemination effect of replacement gilts |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7055291A (en) * | 1990-01-08 | 1991-08-05 | Stefan Heiden | Drug for improving the reactions of the ovary and the production of ova and embryos in domestic mammals in connection with biotechnological embryo transfer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4864019A (en) * | 1985-11-08 | 1989-09-05 | The Salk Institute For Biological Studies | Antibodies to inhibin and conjugates produced therefrom |
| JPH01500121A (en) * | 1986-06-24 | 1989-01-19 | ザ・サルク・インステチュート・フォー・バイオロジカル・スタディーズ | sheep inhibin |
-
1994
- 1994-12-09 JP JP6306274A patent/JP2899534B2/en not_active Expired - Lifetime
-
1995
- 1995-09-12 CA CA 2158116 patent/CA2158116A1/en not_active Abandoned
- 1995-09-15 AU AU31706/95A patent/AU672559B2/en not_active Ceased
- 1995-10-20 FR FR9512359A patent/FR2727866B1/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7055291A (en) * | 1990-01-08 | 1991-08-05 | Stefan Heiden | Drug for improving the reactions of the ovary and the production of ova and embryos in domestic mammals in connection with biotechnological embryo transfer |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2727866B1 (en) | 1999-12-10 |
| CA2158116A1 (en) | 1996-06-10 |
| JP2899534B2 (en) | 1999-06-02 |
| JPH08154957A (en) | 1996-06-18 |
| FR2727866A1 (en) | 1996-06-14 |
| AU3170695A (en) | 1996-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MAHI‐BROWN et al. | Ovarian histopathology of bitches immunized with porcine zonae pellucidae | |
| JPH0848636A (en) | Antibody | |
| US5837497A (en) | DNAs encoding mammalian ZPC and uses thereof | |
| Wrathall et al. | Effects of active immunization against a synthetic peptide sequence of the inhibin α-subunit on plasma gonadotrophin concentrations, ovulation rate and lambing rate in ewes | |
| Suzuki et al. | Seasonal changes in blood IgM levels in goldfish, with special reference to water temperature and gonadal maturation | |
| AU672559B2 (en) | A method of inducing superovulation in cattle | |
| Van Look et al. | Ovulation and lambing rates in ewes actively immunized against androstenedione | |
| Schwoebel et al. | Molecular analysis of the antigenicity and immunogenicity of recombinant zona pellucida antigens in a primate model | |
| Schanbacher et al. | Gonadotrophin concentrations and ovulation rates in Suffolk ewes actively or passively immunized against inhibin alpha | |
| Meyer et al. | Antiserum to an inhibin alpha-chain peptide neutralizes inhibin bioactivity and increases ovulation rate in sheep | |
| Hillard et al. | Immunological manipulation of ovulation rate for twinning in cattle | |
| Fraser et al. | Manipulation of inhibin during the luteal-follicular phase transition of the primate menstrual cycle fails to affect FSH secretion | |
| O'Shea et al. | Active immunization of Merino ewe lambs with recombinant bovine alpha inhibin advances puberty and increases ovulation rate | |
| Barnes et al. | Effect of exogenous FSH on estrus, ovulation and endogenous hormone release in dairy cows | |
| Mei et al. | Enhancing embryo yield in superovulated holstein heifers by immunization against inhibin | |
| US4331657A (en) | Fecundity of domestic livestock | |
| Findlay et al. | Inhibin as a fecundity vaccine | |
| Bazer et al. | The role of ovine conceptus secretory proteins in the establishment of pregnancy | |
| El Tomi et al. | Effects of antibodies to human placental lactogen on reproduction in pregnant rats | |
| Prendiville et al. | Normal or induced secretory patterns of luteinising hormone and follicle-stimulating hormone in anoestrous gonadotrophin-releasing hormone-immunised and cyclic control heifers | |
| Terqui et al. | Modulation of ovarian function by steroid and inhibin immunization | |
| Natraj et al. | Termination of pregnancy in mice following administration of antibodies to the pentadecapeptide 10–24 of chicken riboflavin carrier protein: identification of a bioneutralizing epitope of chicken riboflavin carrier protein | |
| Ireland et al. | Immunoneutralization of inhibin suppresses reproduction in female mink | |
| Roberts et al. | Active immunization of beef heifers against luteinizing hormone: I. Evaluation of protein carriers and adjuvants on antigenicity of LH | |
| US4271069A (en) | Beta-hCG preparation and method |